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Aim: To review milestones in development of oral contraceptive pills since their introduction 
in the US 50 years ago in order to better understand how a new formulation with low-dose 
estrogen in an extended-cycle pattern fits into the evolution of birth control pills.
Methods: This is a review of trends in the development of various birth controls pills and 
includes data from phase III clinical trials for this new formulation.
Results: The first birth control pill was a very high-dose monophasic formulation with the 
prodrug estrogen mestranol and a first-generation progestin. Over the decades, the doses of 
hormones have been markedly reduced, and a new estrogen and several different progestins 
were developed and used in different dosing patterns. The final element to undergo change was 
the 7-day pill-free interval. Many of these same changes have been made in the development 
of extended-cycle pill formulation.
Conclusion: The newest extended-cycle oral contraceptive formulation with 84 active pills, each 
containing 20 µg ethinyl estradiol and 100 µg levonorgestrel, represents an important evolution 
in birth control that incorporates lower doses of estrogen (to reduce side effects and possibly 
reduce risk of thrombosis), fewer scheduled bleeding episodes (to meet women’s desires for 
fewer and shorter menses) and the use of low-dose estrogen in place of placebo pills (to reduce 
the number of days of unscheduled spotting and bleeding). Hopefully, this unique formation 
will motivate women to be more successful contraceptors.
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Introduction
The recent introduction of a low-dose, extended-cycle oral contraceptive pill with 
levonorgestrel (LNG) and ethinyl estradiol (EE) represents an important evolutionary 
step in contraception, reflecting the importance of reducing the hormone levels of the 
active pills while eliminating hormone-free intervals entirely.
To appreciate each of these advances, it is necessary to review briefly the history 
of oral contraceptives (OCs). Such a review is especially relevant as we are celebrat-
ing the 50th year of the introduction of birth control pill in the United States. Despite 
50 years of pill and the availability of many effective contraceptives, nearly half of 
US pregnancies are still unintended. In typical use, the first-year failure rate of OCs is 
8.4%.1 It has been estimated that one million pill users get pregnant each year, usually as 
a result of inconsistent pill use.2,3 In order to help women achieve the full contraceptive 
potential offered by pills with correct and consistent use, several innovative strategies 
have been employed over the years. Lower doses of estrogen have been used to reduce 
side effects such as breast tenderness and nausea, but those lower-dose formulations International Journal of Women’s Health 2010:2 100
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increased the risk of unscheduled spotting and bleeding, and 
early discontinuation.4 At the same time, lower-dose pills may 
not suppress ovarian activity as well as higher-dose OCs.5 The 
pill-free interval has been shortened in some formulations and 
eliminated in others to reduce ovarian folliculogenesis during 
the pill-free interval.6–9 and, thereby, decrease spotting and 
bleeding and the risk of escape ovulation.10,11 Noncontracep-
tive benefits have been popularized to incentivize women to 
use pills more consistently.12
The first formulation approved for contraception 
(Envoid-10®) was a monophasic pill with 21 active pills and 
7 placebo pills. Each active pill contained 150 µg mestranol 
and 9.85 mg norethynodrel. By today’s standards, this is an 
enormous amount of progestin; if a woman were to swallow 
all at once every one of the 21 active pills in a pack of a mod-
ern pills (eg, Ovcon 35®; Warner Chilcott, Rockaway, NJ, 
USA), she would get less progestin than women consumed 
every day with one tablet of Enovid.
While these high doses of sex steroids caused consider-
able side effects, women took these early birth control pills 
with enthusiasm because the pills provided women for the 
first time in history an opportunity to reliably control their 
fertility and the timing of their bleeding. The importance of 
this second feature has not received adequate recognition. 
Rather than having to rearrange their lives at the time of 
their menses, women on the pill could plan their lives around 
predictable (and usually lighter and less painful) scheduled 
bleeding episodes. Both of these features contributed signifi-
cantly to the ability of women to compete more successfully 
in the job market.
The use of placebo pills to induce monthly scheduled 
bleeding (which the user would recognize as the menses) was 
essential to the original acceptance of the pill. Some have 
suggested that the placebo pills were included for political 
reasons – to obtain papal approval of the pill13 – but at the 
time of the pill introduction there were important patient-
based reasons for the placebo pills. Many of the side effects 
that women endured with the early, high-dose pills mimicked 
pregnancy. Nausea and vomiting were frequent problems. 
Breast tenderness and abdominal bloating were also common. 
Melasma was rampant.14 In the face of all these symptoms, 
it was important that women using the pill be reassured that 
they were not pregnant. The only pregnancy test available 
in 1960 was not suitable because it required 6 weeks of 
amenorrhea before it could detect pregnancy and took 2 to 
3 days to perform. However, periodic bleeding induced by 
placebo pills provided users with timely reassurance that they 
were not pregnant and could confidently start use of another 
cycle of pills. The bleeding also calmed women’s concerns 
about possible adverse impacts the pill might have on their 
reproductive system and long-term fertility.
The choice of the number of placebo pills (7) was 
more scientifically based. Even though the so-called “first 
generation” progestins (norethindrone) had relatively short 
half-lives (4 to 8 hours), circulating levels of progestin 
were so high that it often took 4 to 5 days for those levels to 
drop sufficiently to permit endometrial sloughing. To allow 
for variations in metabolic clearance rates so that virtually 
women would start bleeding, 7 days of placebo were used.
New hormones and lower  
doses for birth control pills
Early in the 1960s, the medical hazards posed by high-dose 
estrogen (hypertension and venous and arterial thrombo-
embolism) became apparent. Although these serious events 
were relatively rare, they developed more frequently in 
vulnerable women. In response to these problems, restric-
tions were placed on women who were candidates for oral 
contraceptive use and the doses of estrogen were reduced. 
Women with histories of deep venous thrombosis, myocar-
dial infarction, stroke or hypertension were no longer offered 
pills. The dose of mestranol was reduced first to 100 µg, then 
to 80 µg, and later to 50 µg. The doses of progestin were 
decreased to balance the estrogen doses.
With each reduction in the estrogen (mestranol), a mea-
surable decrease was observed in venous thrombosis (and 
pulmonary embolism).15 Mestranol is a prodrug and requires 
hepatic cleavage to convert it into its active form – ethinyl 
estradiol. The conversion rate varies between individuals, but 
50 µg mestranol is generally equivalent to 35 to 40 µg EE. 
EE replaced mestranol in most of the 50 µg formulations and 
in all the sub-50 pills.
However, as the sex steroids in the active pills were 
reduced, women started to complain more frequently about 
unscheduled spotting and bleeding. In order to minimize 
that problem, longer-acting progestins were developed. 
Norgestrel and LNG (the biologically active dl-norgestrel 
form) significantly decreased the problem of what was called 
at that time “breakthrough bleeding”. Paired with 30 µg EE, 
these new formulations were very popular because they also 
reduced many of the estrogen-related side effects, most 
notably melasma. While LNG provided significant cycle 
control in both its monophasic and multiphasic formulations, 
some users were sensitive to its relatively high androgenicity 
and complained about acne and hirsutism. Clinicians also 
voiced concerns about possible adverse metabolic impacts International Journal of Women’s Health 2010:2 101
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of the relatively androgenic compounds on lipids, especially 
HDL-C and LDL-C.16
In response to those concerns, long-acting progestins 
with less androgenic impact (gestodene, norgestimate and 
desogestrel) were developed. More recently, an antiandro-
genic progestin derived from 17β-spirolactone has been 
marketed. These newer progestins have added new on-label 
noncontraceptive benefits that have been appreciated by 
users. The first approved formulation for treatment of mild to 
moderate acne was a multiphasic norgestimate pill (Ortho Tri-
Cyclen®; Ortho-McNeil-Janssen Pharmaceuticals, Raritan, 
NJ, USA). A low-dose drospirenone-containing formulation 
(Yaz®; Bayer HealthCare, Tarrytown, NY, USA) is Food and 
Drug Administration (FDA) approved for two noncontracep-
tive applications: the treatment of mild to moderate acne and 
the treatment of premenstrual dysphoric disorder (PMDD) in 
women using OCs for birth control. These new applications 
increased both provider and user enthusiasm for their use.
The newer, less androgenic progestins allowed fuller 
expression of the estrogen on hepatic production of SHBG 
(pivotal to success in treatment of acne). As a result, there 
were concerns that hepatic production of thrombotic and 
antithrombotic factors would also be altered by these less 
androgenic formulations and result in increased risk for 
thromboembolism. Large epidemiologic studies in the 1990s 
suggested that the LNG compounds may be associated with 
lower incidence of venous thromboembolic (VTE) events 
(deep venous thrombosis and pulmonary embolism) than 
the less androgenic progestin formulations.17–20 Unfortu-
nately, issues of selection bias and recency of use may have 
compromised the strength of those early findings. However, 
many manufacturers of third-generation progestins in the US 
amended their product labeling to allow for the possibility 
higher risks of VTE with pills with these progestins.
More recently, several very large epidemiologic studies 
with a variety of designs have re-examined this issue. Two 
large-scale studies required by the FDA for post-marketing 
surveillance of drospirenone-containing pills. One study 
provided prospective information on women in Europe (the 
EURAS study).21 In the US a claims-based study compared 
VTE risk using an array of different progestins and different 
doses of estrogen. Those studies found that, when adjusted 
for estrogen dose and known risk factors for thrombosis 
(such as age, obesity), there were no significant differences 
among the rates of VTE, although one study found that the 
LNG formulations did have lower risk of VTE.22 All formula-
tions had much lower VTE risk than pregnancy. Two recent 
claims based and registry based studies from Europe have 
added additional, but less accurate information. The authors 
of those studies concluded that LNG pills posed slightly less 
DVT risk than drospirenone or third-generation progestins, 
but more importantly, they also demonstrated that pills with 
20 µg EE had lower risk of thrombosis than did 30 to 40 µg 
formulations.23,24
Changes in the placebo pills
As early as the 1970s, clinicians found that birth control 
pills could help arrest the growth of endometriotic implants 
by inducing a “pseudo pregnancy” state. When clinicians 
eliminated the placebo pills for months at a time, pills also 
provided relief from the severe dysmenorrhea which women 
with endometriosis suffered.25,26 The most common pills used 
for this indication contained norgestrel/LNG, because the 
long-half of this progestin limited unscheduled bleeding and 
spotting and its potency induced marked therapeutic changes 
in the endometriotic implants. Later, uninterrupted pill use was 
recommended to help women who suffered from menstrual 
migraines.27,28 Episodically, women extended their pill cycles 
to prevent bleeding at inopportune times (honeymoons, travel 
dates, religious holidays). The first product to formally change 
the standard 7 placebo pills, was a low-dose desogestrel-
  containing formulation, (Mircette®; Duramed Pharmaceuticals, 
Pomona, NY, USA) which replaced the last 5 placebo pills with 
5 tablets each with 10 µg EE. This substitution was made to try 
to reduce “estrogen withdrawal” symptoms during the sched-
uled bleeding episodes and as well as to decrease unscheduled 
spotting/bleeding in the subsequent cycle.
A more sustained change in the placebo pills was 
prompted by landmark research conducted by Sulak et al.29 
These investigators persuaded women who wanted to discon-
tinue their OCs because of unpleasant side effects to continue 
using the pills and to chronicle the timing those problems 
in the cycle. If the problems had been randomly distributed, 
the prevalence of problems would have been 3 times greater 
during the 3 weeks of active pill use compared to the 1 week 
of placebo use. If the side effects were due to the hormones 
of the birth control pills, the frequency of problems during 
active pill taking days would be even higher. However, distri-
bution of complaints over the cycle was found to be exactly 
opposite. Women suffered problems such as headache, pelvic 
pain and cramping, breast tenderness, bloating and swelling 
and used pain relievers most often during the placebo-pill 
days (see Table 1). In a follow-up study, Sulak et al found 
that 74% women with pill-free interval problems (such as 
migraine, dysmenorrhea, heavy bleeding, and acne) were 
stabilized on extended-cycle regimens.30International Journal of Women’s Health 2010:2 102
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Willis et al demonstrated the importance of shortening 
(or eliminating) the pill free interval to control ovarian activ-
ity with low-dose pill formulations. Gonadotropins (LH and 
FSH) and ovarian follicular activity (measured by estradiol 
and inhibin B levels) were found to increase greatly after only 
3 to 4 days of placebo use. However, this rise was blunted 
if active pills were started early.31 In another study, women 
who had a 7-day pill-free interval experienced less follicular 
suppression than did women who were supplemented by 
estrogen alone or estrogen plus progestin.32 Ovarian activity 
in overweight women was even less suppressed than seen 
in normal-weight women. Kippling et al demonstrated the 
impact of shortening the pill-free interval by measuring fol-
licle size, estrogen and progesterone levels. With the 7-day 
pill-free interval, no ovulation was observed, but the mean 
dominant follicle size in the next cycle reached 10 mm. With 
a 3-day delay in a start of the next pill pack, that dimension 
reached almost 15 mm, quite capable of ovulation.33 It should 
be noted that with shorter-acting progestins, shortening the 
pill-free interval from 7 to 4 days did not change ovarian 
activity measured by follicle size, Hoogland scores, and 
ovarian steroid hormone production, or change bleeding 
patterns.34
In addition to reducing pill-related complaints, extended-
cycle pills provide significant health benefits. Reducing the 
numbers of scheduled bleeding episodes results in less blood 
loss. This can be very important to women with sickle cell 
anemia, fibroids, bleeding distresses or conditions that require 
use of medications that interfere with vitamin K synthesis. 
The pain and suffering that women experience with their 
monthly bleeding is generally reduced with conventional 
pill use, but extended-cycle use enhances that benefit. With 
menses women suffer back pain, abdominal pain, bloat-
ing, constipation, headache, breast tenderness, irritability, 
depressed mood, fatigue, nausea and even vomiting. These 
complaints are decreased with an extended-cycle oral contra-
ceptive regimen.35 Complaints about headache, mood changes 
and pelvic pain were clearly diminished with extended-cycle 
use of a drospirenone-containing pill compared to its cyclic 
use.36 Estimates are that nearly one-third of the 2.5 million 
US women with menstrual disorders report spending an aver-
age of 9.6 days in bed each year because of these problems.37 
Monthly episodes of these complaints result in lower pro-
ductivity, more lost days of work and less opportunity for 
career advancement. Dysmenorrhea has been reported to 
be the number one cause of lost days of school and work 
in women up to age 25.38 In a Harris poll, 35% of women 
in every age group agreed with the statement that they had 
periodic cramps, and other symptoms that caused interfer-
ence with social events, friends and family, physical/athletic 
opportunity and professional commitments.39
Oral contraceptive formulation 
with extended cycle: first  
FDA-approved product
The first FDA-approved oral contraceptive pill to reduce 
the numbers of scheduled bleeding episodes was a mono-
phasic formulation with 84 days of pills with 30 µg ethinyl 
estradiol and 150 µg LNG, followed by 7 days of placebo 
pills called Seasonale® (Duramed Pharmaceuticals, Pomona, 
NY, USA). Although there was relatively slow uptake of 
this product, women who used it found that it helped them 
overcome another real world barrier that pill users often 
face – the need to return to pharmacies for monthly refills. 
By packing 3 cycles in 1 packet, women had to invest less 
time physically obtaining their pills. The advantage of this 
can be seen in a study of timely contraceptive prescription 
refills which followed 1.7 million women who initiated use 
of wide variety of hormonal contraceptive methods. Of all 
the products studied, there were only two that 30% of women 
refilled on a timely basis for 1 year. Seasonale® was one of 
these products.12
Total numbers of days of spotting and bleeding are 
fewer with the 84/7 formulation (48.2/year) compared to 
the conventional 28-day packets of the same formulation 
(50.8/year).40 Most remarkably, the number of days of sched-
uled bleeding and spotting was not only less with the 84/7 
formulation (10.6/90 days) than with the conventional 21/7 
formulation (34.4/90 days), but the number of days of sched-
uled bleeding after 84 active pills was less than the number of 
days of bleeding during any one scheduled bleeding episode 
using 28 day cycles. The endometrial stripe measured of 
extended-cycle pill on day 84 was also thinner than the endo-
metrial stripe at day 21 with conventional cycling. This is an 
Table 1 Distribution of “pill-related” problems during the pill cycle
Percent of women complaining
   21 days of active  
pills
7 days of placebo 
pills
Complaints*
Pelvic pain 21% 70%
Headache 53% 70%
Breast tenderness 19% 58%
Bloating/swelling 16% 38%
Use of pain medication 43% 69%
From data of Sulak et al.29
*P values for all complaints  0.001 versus placebo.International Journal of Women’s Health 2010:2 103
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important finding, because women who have experienced a 
cycle or two of anovulation know that when their bleeding 
ultimately starts, the flow is heavier and longer than usual. 
Many women worry that extended-cycle OC use will con-
solidate their bleeding into heavier periods. Reassuring them 
that scheduled bleeding is lighter and shorter may remove 
another unspoken fear.
Table 2 shows that total number of days with spotting 
and/or bleeding was less with use of extended-cycle OCs, 
but the median number of days of unscheduled bleeding and 
  spotting days (37.6) was greater than that seen in monthly 
cycling OC users (14.8). However, the median number of days 
of unscheduled spotting and bleeding dropped from 12 days 
in the first 3 months to 6 days in the next 2 cycles. By the 
last packet, the unscheduled spotting and bleeding days with 
extended cycle (about 1 day per 28-day cycle) was the same 
as seen with 28-day-cycle pills.40 Unscheduled bleeding and 
spotting is a feature clinicians fear because of past experience 
with complaints of “breakthrough bleeding” with low-dose 
pills. Counseling before initiation of the extended-cycle pill 
use can diminish those concerns. Women who enrolled in 
the clinical trials were counselled about the probability of 
temporary increase in the numbers of unscheduled days of 
spotting and bleeding; only 7.7% of subjects discontinued 
pill use for “unacceptable bleeding”.40 Efficacy in that trial 
was better for the extended-cycle pill form (0.9% Pearl Index) 
vs conventional 28-day cycle (1.3% Pearl Index). No woman 
with a body weight in excess of 90 kg became pregnant. In a 
systematic Cochrane review of randomized controlled trials 
of extended-cycle oral contraceptive compared to 28-day 
cycles, Edelman et al found that compliance and satisfaction 
were similar. Bleeding patterns were equivalent or improved 
by continuous-dosing regimens but the continuous-dosing 
group had more improvement in menstrual-related problems 
such as headaches, fatigue, bloating and menstrual pain.41
Oral contractive formulations  
with extended cycles: changes  
in the placebo pills
In an attempt to reduce the numbers of days of unscheduled 
bleeding and spotting without increasing the number of 
scheduled bleeding episodes, the next product introduced 
replaced the 7 placebo pills with 7 pills each containing 10 µg 
EE (Seasonique®; Duramed Pharmaceuticals Pomona NY, 
USA). In a study of pituitary – ovarian activity in 3 different 
formulations: 21/7, 84/7 (7 placebo pills) and 84/7 (7 pills 
with EE), investigators found that those receiving the 10 µg 
EE pills had significantly lower levels of both FSH and E2 
(P  0.05). In addition, fewer developing follicles were seen 
during the active pills of the next cycle.6 As expected, both 
the 84/7 placebo and 84/7 EE formulation users reported less 
menstrual flow than did women on 21/7-day regimen.6 In a 
cross-study analysis comparing the outcomes of the phase 3 
trials for each 84/7-day product, it was seen that scheduled 
bleeding with the 84/7-EE regimen was less during in each of 
the scheduled bleeds compared to the 84/7-placebo regimen. 
Also, unscheduled bleeding decreased more quickly with the 
84/7-EE regimen, with significant differences seen during the 
third cycle.42 On an intent-to-treat basis, the Pearl Index was 
1.27 for the newer formulation. This included 2 pregnancies 
in women which occurred within 14 days of discontinuing 
the pills.43 The FDA now requires that these pregnancies be 
counted as contraceptive failures, rather than using them to 
demonstrate rapid return to fertility.
Oral contraceptive formulations 
with extended-cycle: lower-dose 
formulations
Kwiecien et al compared the effects of low-dose (20 µg EE) 
LNG (100 µg) pills given cyclically (21/7) to extended-use 
163/7. Total bleeding days were fewer in the extended-cycle 
group (25.9 vs 34.9 days) and there were fewer bleeding days 
requiring protection in the extended-cycle group (18.4 vs 
33.8 days P  0.01). They also reported significantly fewer 
days of bloating and menstrual pain with extended-cycle 
use.44 When the same pill was used in a randomized, con-
trolled study comparing 12 cycles of uninterrupted use to 
a conventional 21/7 regimen, fewer total days of bleed-
ing occurred in the continuous-use arm.45 In a different 
study, which directly compared days of amenorrhea with 
Table 2 Bleeding patterns with 30 µg EE/150 LNG pills given in 
extended cycles vs conventional cycle
Number of days in 1 year
  Extended cycle 28-day cycle
Total days of Mean Median Mean Median
  Bleeding and/or spotting 48.2 35 50.8 53
  Bleeding only 22.7 16.0 37.0 39.5
Scheduled days
  Bleeding and/or spotting 10.6 10.0 32.4 36.0
  Bleeding only 7.9 2.0 27.0 29.0
Unscheduled days
  Bleeding and/or spotting 37.6 26.0 14.8 7.0
  Bleeding only 18.3 13.0 9.9 5.5
From data of Anderson et al.40International Journal of Women’s Health 2010:2 104
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extended-cycle use, the LNG arm with 20 µg EE pills resulted 
in a higher median number of days of amenorrhea during the 
first 90 days (71 days) than was seen in the 30 µg EE/LNG 
arm (67 days). There were also fewer days of spotting in the 
lower-dose arm.46
The FDA approved a low-dose continuous regimen of 
20 µg EE/90 µg LNG pills that were used for up to 13 cycles 
of use (Lybrel®; Wyeth Pharmaceutical, Philadelphia, PA, 
USA). The Pearl Index pregnancy rate was 1.60 on-treatment. 
The onset of amenorrhea (no bleeding or spotting) was some-
what slow with this formulation, but by cycle 13, 58.7% of 
subjects had complete amenorrhea and another 23.0% had 
only spotting but no bleeding. Only 921 of the 2134 women 
who took at least 1 dose of drug completed the 12-month 
study; 56% of study participants discontinued early.47
More recently, a randomized open-label European study 
of daily use of pills with 20 µg EE/90 µg LNG vs cyclic use 
of pills with (21/7) 20 µg EE/100 µg LNG, reported that 
there were no pregnancies in the continuous OC arm, but the 
Pearl Index in the cyclic OC arm was 1.19. Amenorrhea was 
achieved by 40% of women in the extended-cycle arm by pill 
pack 7 and by 53% by the last cycle. Another 26% had only 
spotting by that last cycle.48 The discontinuation rate for the 
continuous formulation was 33.1% compared to 21.7% in the 
cyclic arm. Many other features of this formulation have been 
reported. Continuous pill use completely suppressed ovula-
tion, with little evidence of follicular development during a 
90-day study. Return of ovulation after cessation was rapid.49 
In a study of explicit return to fertility, the pregnancy rate was 
52% by 3 months after cessation, and 86% at 13 months.50 
Median return to menses was 32 days; 98.9% of women 
had return of menses or pregnancy by 90 days.51 To prevent 
possible confusion between anovulatory causes of amenor-
rhea (which could place a woman at risk for endometrial 
hyperplasia) and menstrual suppression with continuous 
combination OCs, endometrial safety with this continuous 
formulation was demonstrated by endometrial aspiration 
at the end of 13 cycles; no hyperplasia or malignancy was 
detected.52 Finally, adverse menstrual-cycle related symptoms 
were significantly improved within 3 months of initiation or 
continuous OCs.53 The Endicott Work Productivity Scale 
also showed improved with continuous OC use compared to 
baseline.54 Only 18.6% of women in this study discontinued 
pill use.
The latest FDA-approved in extended-cycle contraceptive 
pill is an 84/7 formulation with 84 tablets of 20 µg EE/100 µg 
LNG and 7 tablets with 10 µg EE each – Lo Seasonique® 
(Duramed Pharmaceuticals, Pomona, New York, USA). This 
formulation builds on the popularity of low-dose estrogen. 
This formulation has a slightly higher dose of progestin 
(100 µg vs 90 µg) than the prior FDA-approved 13-cycle 
product (Lybrel®). The 100 µg dose is equivalent to the dose 
used in the open label European study of continuous OCs. 
Four scheduled bleeding episodes are induced each year to 
meet the desires of many women to reduce, but not elimi-
nate their “menstruation”55,39 and to more rapidly reduce the 
  numbers of days of unscheduled bleeding and spotting.
In the phase 3 clinical trial, 2,185 women provided 20,937 
28-day cycles of exposure.56 Women aged 18 to 40 were stud-
ied for safety outcomes. Pregnancy rates were calculated for 
the group as a whole and for women age 18 to 35. The Pearl 
Index for pregnancies in the 18 to 35 age group in their intent 
to treat population adjusted for use of other methods was 
2.74, including pregnancies that occurred within 14 days of 
drug cessation. Three of the pregnancies were never verified 
and 4 occurred in the second week following pill cessation. 
Interestingly, the weight of the subjects in this study was 
very representative of typical American women; they ranged 
from 87 to 381 pounds (40 to 175 kg), with a mean weight of 
158.7 pounds (72.8 kg). Over a quarter of women were obese 
and 12.4% had BMI  40. Earlier retrospective studies had 
voiced the concern that lower-dose OCs may be associated 
with higher pregnancy rates among women weighing more 
than 70 kg.57,58 In this clinical study, there was no trend to 
increased pregnancy rates in heavier women. Distributing the 
women into deciles based on weight at entry into the study, 
the lowest pregnancy rate (0.47%) was seen in the sixth decile 
and the highest (2.75%) was found in the fifth decile.
Scheduled bleeding and/or spotting usually lasted 2 to 
3 days every 91-day cycle. Unscheduled spotting and bleed-
ing diminished progressively with longer use. The median 
number of days with unscheduled bleeding in the first 91-day 
period was 15 and unscheduled spotting added a median 
of 10 days during the first 91-day cycle (2.5 days/28 day 
cycle). By the fourth cycle, the median number of unsched-
uled bleeding days was 0, and the median number days of 
unscheduled spotting was 3 per 91-day cycle. Looking at 
the data another way, it can be seen that 44% of women 
had at least 20 days (more than 6 days per 28-day cycle) 
of unscheduled bleeding and spotting the first cycle, but by 
the fourth cycle only 19% of women had that extensive a 
problem. Interestingly, of those 19%, only 3% had prolonged 
bleeding; the other 16% experienced only prolonged spotting. 
Complete amenorrhea was reported by 6.2% of subjects first 
cycle and by 17.4% in the last cycle. In this study, 57.2% of 
women completed the entire trial; 9.6% discontinued early, International Journal of Women’s Health 2010:2 105
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at least in part due to bleeding and/or spotting.57 These 
numbers compare quite favorably to the pattern seen with 
higher-dose (30 µg EE) 84/7 (placebo) formulation. The 
safety profile was reported to be similar to that found with 
other OCs. Importantly, even in this heavier, older study 
population, there were no reports of venous thromboembolic 
events.
Conclusion
As we celebrate the 50th anniversary of the first birth control 
pill, it is interesting to reflect on the many changes that birth 
control pills have undergone in response to patient prefer-
ences and safety considerations. One of the last features of 
the birth control pill to change was the number and content 
of placebo pills. Once it was recognized that scheduled 
bleeding with birth control pills has no medical benefit and 
can cause suffering and discontent with pills, products with 
extended cycles were introduced. Those products have over 
time repeated much of the history of the earlier monthly 
cyclic formulations. This latest extended formula represents 
many of the evolutionary changes that have been made to “the 
pill” to increase pill safety (decreased estrogen doses) and to 
encourage correct and consistent pill use by minimizing side 
effects (unscheduled bleeding and spotting) and by providing 
important noncontraceptive benefits (decreased numbers of 
scheduled bleeding episodes). It has been tested in women 
who more accurately reflect the US population in weight. 
By advancing in all of these important directions, this new 
formation represents an important new option to help women 
more successfully contracept.
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